All In Biotech

Drug Trial Radar · NCT03395535

Laser-1st vs Drops-1st for Glaucoma and Ocular Hypertension

Health-Related Quality of Life in Two Pathways for Newly Diagnosed Open Angle Glaucoma and Ocular Hypertension: an Unmasked, Multi-centre, Randomised Controlled Trial of Initial Selective Laser Trabeculoplasty Versus Medical Therapy

Last checked: Nov 19, 2026Latest source record: Jan 10, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 718 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

718

Actual

Start

Oct 1, 2012

Primary completion

Dec 25, 2017

Study completion Dec 25, 2017

Sponsor

Lead sponsor
Moorfields Eye Hospital NHS Foundation TrustAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jan 10, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Single group
Masking
Single (outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a randomized study with two treatment arms: 'initial Selective Laser Trabeculoplasty (SLT) followed by conventional medical therapy as required' ('Laser-1st') and 'medical therapy without laser ('Medicine-1st'). It compares quality of life in the two arms at three years, while also examining the incremental cost and cost-effectiveness of Laser-1st versus Medicine-1st.

Conditions

  • Primary Open Angle Glaucoma
  • Ocular Hypertension

Interventions

  • Primary Selective Laser Trabeculoplasty Treatment PathwayProcedure

    Primary Selective Laser Trabeculoplasty Treatment (followed by medications as required) Pathway. First treatment is SLT, 100 shots of laser over 360 degrees. If this does not reach the target IOP then repeat laser (once only) is given. If IOP not at target additional treatment with all standard medications may be used and ultimately surgery (trabeculectomy ). All available medical treatments (eye-drops) are permitted according to a pre-specified intervention protocol described in detail in the publicly available trial protocol. This begins with prostaglandin analogues, then beta-blockers followed by alpha agonists or carbonic anhydrase inhibitors. The full range of available doses, treatments and drugs is beyond this short summary.

  • Primary Medical Treatment PathwayDrug

    Primary Medical Treatment Pathway (multiple medications, as required). If IOP not at target additional treatment with all standard medications may be used and ultimately surgery (trabeculectomy ). All available medical treatments (eye-drops) are permitted according to a pre-specified intervention protocol described in detail in the publicly available trial protocol. This begins with prostaglandin analogues, then beta-blockers followed by alpha agonists or carbonic anhydrase inhibitors. The full range of available doses, treatments and drugs is beyond this short summary.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Health Related Quality of Life using EQ-5DTime frame: 3 years

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Moorfields Eye Hospital

    London, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.